Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias)
Fernandez del Valle, Ana (Hospital Universitario Central de Asturias)
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia))
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid))
Custodio, Ana (Hospital Universitario La Paz (Madrid))
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid))
Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile))
Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia))
Matos, Ignacio (Hospital Universitari Vall d'Hebron)
Alonso-Orduña, Vícente (Hospital Universitario Miguel Servet (Saragossa))
Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Viudez, Antonio (Complejo Hospitalario de Navarra)
Izquierdo, Marta (Hospital Universitario Central de Asturias)
Calvo-Temprano, David (Hospital Universitario Central de Asturias)
Grande, Enrique (MD Anderson Cancer Center)
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias)
Universitat Autònoma de Barcelona
Vall d'Hebron Institut d'Oncologia

Data:	2019
Resum:	The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11. 42 (95% confidence interval [CI], 9. 7-15. 9) and 15. 8 months (95% CI, 13. 9-25. 7). PFS by Choi (Kendall's τ = 0. 72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0. 43). RECIST incorrectly estimated prognosis in 49. 6%. Partial response rate increased from 12. 8% to 47. 4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cancer imaging ; Neuroendocrine cancer
Publicat a:	British journal of cancer, Vol. 121 (september 2019) , p. 537-544, ISSN 1532-1827

DOI: 10.1038/s41416-019-0558-7
PMID: 31477779

8 p, 518.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats